

INPLASY PROTOCOL

To cite: Wang et al. Efficacy and safety of burosumab in X-linked hypophosphataemia: Systematic review and meta-analysis. Inplasy protocol 202280058. doi: 10.37766/inplasy2022.8.0058

Received: 15 August 2022

Published: 15 August 2022

Corresponding author:
Sen Wang

wangsen0652@qq.com

Author Affiliation:
Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University.

Support: NO. 2016MSXM080 Medical Science.

Review Stage at time of this submission: Completed but not published.

Conflicts of interest:
None declared.

INTRODUCTION

Review question / Objective: Burosumab, a fully human monoclonal antibody to fibroblast growth factor 23 (FGF23), is approved for the treatment of X-linked hypophosphataemia (XLH), the most common inherited form of rickets. To

Efficacy and safety of burosumab in X-linked hypophosphataemia: Systematic review and meta-analysis

Wang, S¹; Wang, XQ²; He, M³; Li, YF⁴; Xiao, MH⁵; Ma, HX⁶.

Review question / Objective: Burosumab, a fully human monoclonal antibody to fibroblast growth factor 23 (FGF23), is approved for the treatment of X-linked hypophosphataemia (XLH), the most common inherited form of rickets. To assess the efficacy and safety of burosumab in patients with XLH, we conducted a systematic review and meta-analysis. X-linked hypophosphataemia.

Condition being studied: X-linked hypophosphataemia (XLH) is the most common genetic cause of rickets, which is caused by a loss-of-function mutation in the phosphate regulated endopeptidase homologous gene, X-linked gene [1, 2]. The disease is characterised by the increased concentrations of fibroblast growth factor 23 (FGF23) in the blood, resulting in hypophosphataemia by increasing phosphoruria and inhibiting the synthesis of 1,25-dihydroxyvitamin D (1,25(OH)₂D). Hypophosphataemia and defects in bone mineralisation can result in rickets, osteomalacia, skeletal deformities and short stature, which persists into adulthood and are accompanied by impaired physical function and musculoskeletal pain.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 15 August 2022 and was last updated on 15 October 2022 (registration number INPLASY202280058).

assess the efficacy and safety of burosumab in patients with XLH, we conducted a systematic review and meta-analysis. X-linked hypophosphataemia

Condition being studied: X-linked hypophosphataemia (XLH) is the most common genetic cause of rickets, which is

caused by a loss-of-function mutation in the phosphate regulated endopeptidase homologous gene, X-linked gene[1, 2]. The disease is characterised by the increased concentrations of fibroblast growth factor 23 (FGF23) in the blood, resulting in hypophosphataemia by increasing phosphoruria and inhibiting the synthesis of 1,25-dihydroxyvitamin D (1,25(OH)₂ D). Hypophosphataemia and defects in bone mineralisation can result in rickets, osteomalacia, skeletal deformities and short stature, which persists into adulthood and are accompanied by impaired physical function and musculoskeletal pain.

METHODS

Search strategy: The literature search was conducted using PubMed, Embase, ClinicalTrials.gov, Web of Science and the Cochrane Library up to August 1, 2022. The medical subject heading keywords including “Burosumab,” “KRN23,” “X-linked hypophosphataemia,” “Hypophosphatemic Rickets, X-Linked.” was used to search for burosumab and X-linked hypophosphataemia. To ensure a comprehensive literature search, we also screened reference lists from included articles. The ClinicalTrials.gov website was searched for ongoing but unpublished trials in this field.

Participant or population: Patients with XLH.

Intervention: Burosumab.

Comparator: Placebo or traditional treatment.

Study designs to be included: randomized controlled trials and single-arm trials.

Eligibility criteria: We included trials of all designs, including randomized controlled trials (RCTs), non-randomized controlled trials and single-arm trials (SATs). Studies included in this meta-analysis satisfied the following criteria: (1) interventions using burosumab ; (2) Studies must have been published in peer-reviewed academic journals or as part of scientific conference

proceedings. The available data were used to calculate the corresponding statistics. Meeting abstracts, animal studies, and review articles were not included.

Information sources: PubMed, Embase, ClinicalTrials.gov, Web of Science and the Cochrane Library, reference lists from included articles.

Main outcome(s): Serum Phosphorus Levels, TmP/GFR, 1,25(OH)₂D. Measures of effect: Serum Phosphorus Levels is a valid indicator in X-linked hypophosphatemia, a rare genetic disorder characterized by renal phosphate wasting. TmP/GFR is defined as the tubular maximum for phosphate reabsorption per glomerular filtration rate. 1,25(OH)₂D is defined as serum 1,25-dihydroxyvitamin D. In X-linked hypophosphatemia, excess FGF23 impairs renal phosphate reabsorption and reduces serum 1,25(OH)₂D, resulting in chronic hypophosphatemia, rickets, and osteomalacia. The effect measures will be net change of the outcomes of interest.

Additional outcome(s): ALP, recumbent length and standing height Z score, 6MWT%, RSS, and RGI-C total score. Adverse Event: plasma intact parathyroid hormone, serum calcium, urine calcium excretion, nephrocalcinosis scores, any TEAE rate, serious TEAE rate, the incidence of headache, injection site reaction event and arthralgia. Measures of effect: ALP is defined as serum alkaline phosphatase concentration. 6MWT% is defined as percent predicted distance walked in the 6-minute walk test. RSS is defined as the thacher rickets severity score. RGI-C total score is defined as the radiographic global impression of change. TEAE is defined as treatment emergency adverse event.

Quality assessment / Risk of bias analysis: We assessed the methodological quality (risk of bias) of each RCT in accordance with the Cochrane Risk of Bias Tool (CCRBT) for the randomized clinical trials. Risk of bias was determined in duplicate, and discrepancies were resolved by consensus in group discussion. The

methodological index for non-randomized studies (MINORS) was also used to assess the overall quality of the SATs.

Strategy of data synthesis: We performed separate analyses for randomized controlled trials and single-arm studies. For RCTs, we computed net differences as Net change = (burosumab at final – burosumab at baseline) – (control at final – control at baseline) for outcomes. For single arm trials, we computed change in outcomes as (Change = burosumab at final – burosumab at baseline). The meta-analysis was carried out using the Review Manager (version: 5.4) and Stata platform (version: 15.1), and the combined effect was expressed as a weighted mean difference (WMD) and its 95% confidence interval (CI), that is, WMD (95 percent CI). The heterogeneity test was applied to the studies, and heterogeneity is considered low when I² is >50%. Moreover, the outcome indicators were combined using the fixed-effect model, and if I² ≥ 50%, it is considered that there is more than moderate heterogeneity. Additionally, to combine the outcome indicators, the random-effect model is applied.

Subgroup analysis: Based on the administration frequency outcomes were divided to q2w group and q4w group.

Sensitivity analysis: Sensitivity analysis was not performed.

Country(ies) involved: China.

Keywords: Burosumab, X-linked hypophosphataemia, monoclonal antibody, fibroblast growth factor 23, serum phosphorus, adverse event, meta-analysis.

Contributions of each author:

Author 1 - Sen Wang.

Email: wangsen0652@qq.com

Author 2 - Xiaoqin Wang.

Author 3 - Miao He.

Author 4 - Yuanfen Li.

Author 5 - Minghui Xiao.

Author 6 - Houxun Ma.